In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online ...

Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...

Myriad Genetics, Inc. SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a ...

Myriad Genetics Inc (MYGN) stock saw a decline, ending the day at $12.39 which represents a decrease of $-0.13 or -1.04% from the prior close of $12.52. The stock opened at $12.56 and touched a low of ...

A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...

Myriad Genetics, Inc. announced its preliminary financial results for the fourth quarter and full year of 2024, projecting total revenues of $209 million to $211 million for Q4 and $836 million to ...

M, consensus $212.84M Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...

Myriad Genetics partners with broadcaster Hannah Storm to promote breast cancer risk assessment and the importance of family health history. Myriad Genetics, Inc. has announced a collaboration ...

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for ...